Solventum (NYSE:SOLV) Announces Earnings Results

Solventum (NYSE:SOLV) posted its earnings results on Wednesday. The company reported $2.55 EPS for the quarter, beating the consensus estimate of $1.91 by $0.64, FiscalAI reports. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.15 billion. During the same period last year, the company earned $1.69 earnings per share. The business’s quarterly revenue was up 2.2% on a year-over-year basis. Solventum updated its FY 2026 guidance to 7.100-7.200 EPS.

Here are the key takeaways from Solventum’s conference call:

• Solventum reported a strong Q2, with 9.5% organic sales growth, adjusted EPS of $2.55, and performance ahead of plan across all segments. Results benefited from approximately $125 million of ERP-related advanced orders and a $100 million tariff refund.
• Management raised 2026 guidance, including organic growth to 2.5%-3% excluding SKU exits (3.5%-4% on an ex-SKU basis), operating margin to 22.2%-22.7%, and EPS to $7.10-$7.20 from $6.40-$6.60.
• The ERP advanced orders are expected to mostly reverse in Q3, creating an anticipated 3%-4% decline in quarterly sales growth and a roughly $0.34 EPS headwind before a projected return to 3%-4% growth in Q4.
• Solventum is advancing the separation of its Health Information Systems business, believing an independent company or combination with a larger healthcare IT player could unlock value while allowing Solventum to focus on MedSurg and Dental. However, the process is still at an early stage and the transaction structure, timing, proceeds, and potential EPS impact remain uncertain.
• Acera continued to outperform, with revenue growth above 40% and gross margin above 80%, while management cited a multi-billion-dollar opportunity from underpenetrated growth drivers, including IV site management, wound care, sterilization, dental aesthetics, and AI-enabled coding.

Solventum Stock Down 0.8%

Shares of SOLV stock traded down $0.68 on Wednesday, reaching $87.26. 1,552,465 shares of the company were exchanged, compared to its average volume of 1,084,826. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. The company has a 50-day moving average of $79.09 and a 200-day moving average of $74.36. The company has a market cap of $15.11 billion, a price-to-earnings ratio of 10.69, a PEG ratio of 1.36 and a beta of 0.60. Solventum has a one year low of $62.38 and a one year high of $88.65.

Key Solventum News

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Second-quarter adjusted earnings per share were $2.55, well above analysts’ expectations of approximately $1.90-$1.91. Revenue reached $2.21 billion, exceeding the $2.15 billion consensus estimate. Solventum Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Sales increased 2.2% year over year, while organic sales growth was a stronger 9.5%, suggesting improving underlying demand despite reported revenue growth being affected by portfolio or currency factors. Solventum Q2 Earnings Metrics
• Positive Sentiment: Solventum raised its full-year 2026 guidance, including adjusted EPS of $7.10-$7.20 versus consensus near $6.55-$6.58. The company also increased expectations for organic sales growth and free cash flow, strengthening the earnings outlook. Solventum Raises Profit Forecast
• Neutral Sentiment: The company intends to separate its Health Information Systems business, positioning Solventum as a more focused medical-technology company while allowing the healthcare software unit to pursue its own growth strategy. The move could unlock shareholder value, but investors will watch the separation’s structure, costs and execution. Solventum Health Information Systems Separation

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in SOLV. Boston Partners increased its holdings in shares of Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after acquiring an additional 959,543 shares in the last quarter. Balyasny Asset Management L.P. acquired a new position in shares of Solventum during the third quarter worth approximately $42,393,000. Raymond James Financial Inc. lifted its holdings in shares of Solventum by 116.5% in the 3rd quarter. Raymond James Financial Inc. now owns 702,411 shares of the company’s stock worth $51,276,000 after purchasing an additional 378,024 shares in the last quarter. Zimmer Partners LP bought a new position in shares of Solventum in the 3rd quarter worth $20,075,000. Finally, AQR Capital Management LLC grew its position in Solventum by 82.0% in the 4th quarter. AQR Capital Management LLC now owns 469,288 shares of the company’s stock valued at $37,186,000 after purchasing an additional 211,440 shares during the period.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. BMO Capital Markets began coverage on Solventum in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price objective for the company. BTIG Research reiterated a “buy” rating and set a $91.00 price target on shares of Solventum in a report on Monday, July 13th. UBS Group raised shares of Solventum from a “neutral” rating to a “buy” rating and set a $95.00 price objective on the stock in a research note on Tuesday, July 28th. Stifel Nicolaus decreased their price objective on Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Finally, Weiss Ratings raised Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, July 17th. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Solventum has a consensus rating of “Hold” and a consensus price target of $86.00.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.